HAUPPAUGE, N.Y.--(BUSINESS WIRE)--MDS Property Management Software is pleased to announce the successful completion of its System and Organization Controls (SOC) 2 audit, achieving compliance with the ...

Exploring the impact of inflammation in MDS, this article highlights the need for novel therapies to enhance patient quality ...

Amer Zeidan, MBBS, MHS: The management of patients with myelodysplastic syndrome [MDS] is largely connected to the risk-stratification status of the patients. Patients who have high-risk disease are ...

Since the late 1990’s, the Minimum Data Set has been a primary driver in the long-term care industry, influencing all areas of skilled nursing facility operations. The clinical data that are collected ...

Without a doubt, the MDS 3.0, like its predecessor MDS 2.0, is the driver for skilled nursing facilities. Some might say it’s driving us “to drink,” but truly it is the measure by which we are paid, ...

In his closing thoughts, Dr Garcia-Manero provides an overview of the treatment management approach for patients with MDS. Guillermo Garcia-Manero, MD: I think the bottom line is these data suggest ...

December 19, 2011 (San Diego, California) — A survey asking nearly 2000 hematology/oncology providers in the United States how they would treat patients with myelodysplastic syndrome (MDS) has ...

It is a well-known phenomenon that MDs and MBAs approach healthcare from very different perspectives, yet their respective roles and objectives are becoming dependent upon successful collaboration ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the ...